CV: Cardiovascular. CAD: Coronary artery disease. PAD: Peripheral artery disease.
MI: Myocardial infarction.
^* In addition to reducing the risk of CV death when added to the standard of care, JARDIANCE® also lowered glucose.
In addition, JARDIANCE® demonstrated reduction in weight and blood pressure. JARDIANCE® is not indicated for weight loss or reduction of blood pressure..²
_{† Adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke.^1,2}

1. Jardiance^® approved prescribing information, Boehringer lngelheim India, Version 28th Feb, 2020.
2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.

1. Data on file. Boehringer lngelheim Pharmaceuticals, Inc.

CV: Cardiovascular. RRR: Relative risk reduction. HR: Hazard ratio. CI: Confidence interval. MI: Myocardial infarction.
CAD: Coronary artery disease. PAD: Peripheral artery disease.
Primary outcome was reduction in CV events defined as composite endpoint of CV death, non-fatal MI, or non-fatal stroke.
Jardiance^® reduced the relative risk of CV events by 14% (HR=0.86; 95.02% CI: 0.74, 0.99; p=0.04). CV death was significantly reduced by
38% with no significant difference in non-fatal MI or non-fatal stroke.^1,2
* Adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke.^1,2
† The 38% RRR in CV death was achieved in the overall EMPA-REG OUTCOME^® population for the duration of the trial.^1,3
‡ Pooled data from 10 mg and 25 mg doses of Jardiance^®; both doses showed a comparable reduction in the risk of CV death.^1,2
§ A post-hoc analysis of data from the EMPA-REG OUTCOME^® Trial by baseline HbA1c subgroups. EMPA-REG OUTCOME® was not powered to show differences between sub-groups.^2,4
|| Hazard ratios are related to CV death: HbA1c <7% HR=0.30 (95% CI: 0.12, 0.80); HbA1c 7% to <8% HR=0.59 (95% CI: 0.42, 0.83); HbA1c 8% to <9% HR=0.67 (95% CI: 0.45, 0.99); HbA1c ≥9% HR=0.76 (95% CI: 0.44, 1.31); p=0.41 for interaction.4

1. Jardiance^® approved prescribing information, Boehringer lngelheim India, Version 28th Feb, 2020.
2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
3. Fitchett D, Inzucchi SE, Lachin JM, et al. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease. J Am Coll Cardiol. 2018;71(3):364-367.
4. Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation. 2018;138:1904-1907.
5. Claggett B, Lachin JM, Hantel S, et al. Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular disease: Survival estimates from the EMPA-REG OUTCOME^® Trial. Circulation. 2018;138:1599-1601.
6. Piepoli MF, Hoes AW, Agewall S, et al. European Guidelines on cardiovascular disease prevention in clinicalpractice: The Sixth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2016;37(29):2315-2381.

GLP-1: Glucagon-like peptide-1. SGLT2i: Sodium-glucose co-transporter 2 inhibitor. ADA: American Diabetes Association. EASD: European Association for the Study of Diabetes. CVD: Cardiovascular disease.

1. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701.

CAD: Coronary artery disease. RRR: Relative risk reduction. ACEi: Angiotensin-converting enzyme inhibitor. ARB: Angiotensin II receptor blocker. HF: Heart failure. HbA1c: Glycated haemoglobin. HR: Hazard Ratio. CI: Confidence interval.
^* Adult patients with type 2 diabetes and CAD, PAD, or a history of MI or stroke.^1,2,3
† Hospitalisation for heart failure was a secondary CV outcome in the EMPA-REG OUTCOME^® trial (HR=0.65; 95% CI: 0.50, 0.85).^1,3
‡ Pooled data from 10-mg and 25-mg doses of Jardiance^®; both doses showed a comparable reduction in the risk of hospitalisation for heart failure.²

1. Jardiance^® approved prescribing information, Boehringer Ingelheim India , Version 19th Nov 2018.
2. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME^® Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
3. Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME^®). Cardiovasc Diabetol. 2014;13(102).

CV: Cardiovascular. CAD: Coronary artery disease. PAD: Peripheral artery disease. MI: Myocardial infarction.
^* Adult patients with type 2 diabetes and CAD, PAD, or a history of MI or stroke.^{1,2,6 †} Hospitalisation for heart failure was a secondary CV outcome in the EMPA-REG OUTCOME^® trial.⁶

1. Jardiance^® approved prescribing information, Boehringer Ingelheim India, Version 19^th Nov 2018.
2. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME^® Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
3. JANUVIA [summary of product characteristics]. Hertfordshire, United Kingdom: Merck Sharp & Dohme Ltd.; June 2018.
4. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232-242.
5. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.
6. Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME^® sitagliptin). Cardiovasc Diabetol. 2014;13(102).

1. Data on file. Boehringer Ingelheim. Available at https://www.prnewswire.com/news-releases/the-galien-foundation-announces-2018-prix-galien-international-award-recipents-300756911.html. Last accessed on 17th Dec 2018.